Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Woolsey C, Menicucci AR, Cross RW, Luthra P, Agans KN, Borisevich V, Geisbert JB, Mire CE, Fenton KA, Jankeel A, Anand S, Ebihara H, Geisbert TW, Messaoudi I, Basler CF.

Cell Rep. 2019 Sep 17;28(12):3032-3046.e6. doi: 10.1016/j.celrep.2019.08.047.

PMID:
31533029
2.

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus.

Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, Nambu A, Bavari S, Soloveva V, Sadukhan S, Cassell GH, Geisbert TW, Hur S, Goldfeld AE.

iScience. 2019 Jul 24. pii: S2589-0042(19)30228-7. doi: 10.1016/j.isci.2019.07.003. [Epub ahead of print]

3.

Antibody therapy for Lassa fever.

Cross RW, Hastie KM, Mire CE, Robinson JE, Geisbert TW, Branco LM, Ollmann Saphire E, Garry RF.

Curr Opin Virol. 2019 Aug 8;37:97-104. doi: 10.1016/j.coviro.2019.07.003. [Epub ahead of print] Review.

PMID:
31401518
4.

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Hastie KM, Cross RW, Harkins SS, Zandonatti MA, Koval AP, Heinrich ML, Rowland MM, Robinson JE, Geisbert TW, Garry RF, Branco LM, Saphire EO.

Cell. 2019 Aug 8;178(4):1004-1015.e14. doi: 10.1016/j.cell.2019.07.020.

PMID:
31398326
5.

Use of reverse genetics to inform Ebola outbreak responses.

Cross RW, Geisbert TW.

Lancet Infect Dis. 2019 Sep;19(9):925-927. doi: 10.1016/S1473-3099(19)30346-9. Epub 2019 Jul 9. No abstract available.

PMID:
31300333
6.

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.

Rodriguez SE, Cross RW, Fenton KA, Bente DA, Mire CE, Geisbert TW.

Sci Rep. 2019 May 23;9(1):7755. doi: 10.1038/s41598-019-44210-6.

7.

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.

Mire CE, Geisbert JB, Agans KN, Versteeg KM, Deer DJ, Satterfield BA, Fenton KA, Geisbert TW.

Emerg Infect Dis. 2019 Jun;25(6):1144-1152. doi: 10.3201/eid2506.181620.

8.

Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2019 May 8;9(1):7329. doi: 10.1038/s41598-019-42949-6.

9.

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.

Bornholdt ZA, Herbert AS, Mire CE, He S, Cross RW, Wec AZ, Abelson DM, Geisbert JB, James RM, Rahim MN, Zhu W, Borisevich V, Banadyga L, Gunn BM, Agans KN, Wirchnianski AS, Goodwin E, Tierney K, Shestowsky WS, Bohorov O, Bohorova N, Velasco J, Ailor E, Kim D, Pauly MH, Whaley KJ, Alter G, Walker LM, Chandran K, Zeitlin L, Qiu X, Geisbert TW, Dye JM.

Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5. doi: 10.1016/j.chom.2018.12.005.

PMID:
30629918
10.

Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans.

Cross RW, Speranza E, Borisevich V, Widen SG, Wood TG, Shim RS, Adams RD, Gerhardt DM, Bennett RS, Honko AN, Johnson JC, Hensley LE, Geisbert TW, Connor JH.

J Infect Dis. 2018 Nov 22;218(suppl_5):S486-S495. doi: 10.1093/infdis/jiy455.

11.

Small animal models of filovirus disease: recent advances and future directions.

Cross RW, Fenton KA, Geisbert TW.

Expert Opin Drug Discov. 2018 Nov;13(11):1027-1040. doi: 10.1080/17460441.2018.1527827. Epub 2018 Sep 29. Review.

PMID:
30269599
12.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Nov 22;218(suppl_5):S565-S573. doi: 10.1093/infdis/jiy295.

PMID:
29982718
13.

Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo).

Cross RW, Mire CE, Agans KN, Borisevich V, Fenton KA, Geisbert TW.

J Infect Dis. 2018 Nov 22;218(suppl_5):S448-S452. doi: 10.1093/infdis/jiy268.

14.

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.

Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ.

J Infect Dis. 2018 Nov 22;218(suppl_5):S553-S564. doi: 10.1093/infdis/jiy316.

PMID:
29939318
15.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Nov 22;218(suppl_5):S582-S587. doi: 10.1093/infdis/jiy293.

16.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 May 4. doi: 10.1038/nrd.2018.73. [Epub ahead of print] No abstract available.

PMID:
29725132
17.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

18.

Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.

Boisen ML, Hartnett JN, Shaffer JG, Goba A, Momoh M, Sandi JD, Fullah M, Nelson DKS, Bush DJ, Rowland MM, Heinrich ML, Koval AP, Cross RW, Barnes KG, Lachenauer AE, Lin AE, Nekoui M, Kotliar D, Winnicki SM, Siddle KJ, Gbakie M, Fonnie M, Koroma VJ, Kanneh L, Kulakosky PC, Hastie KM, Wilson RB, Andersen KG, Folarin OO, Happi CT, Sabeti PC, Geisbert TW, Saphire EO, Khan SH, Grant DS, Schieffelin JS, Branco LM, Garry RF.

Sci Rep. 2018 Apr 12;8(1):5939. doi: 10.1038/s41598-018-24246-w.

19.

Predicting outcome and improving treatment for Lassa fever.

Geisbert TW.

Lancet Infect Dis. 2018 Jun;18(6):594-595. doi: 10.1016/S1473-3099(18)30116-6. Epub 2018 Mar 6. No abstract available.

PMID:
29523495
20.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

21.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 Jun;17(6):413-434. doi: 10.1038/nrd.2017.251. Epub 2018 Jan 29. Review. Erratum in: Nat Rev Drug Discov. 2018 May 04;:.

PMID:
29375139
22.

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2018 Jan 17;92(3). pii: e01190-17. doi: 10.1128/JVI.01190-17. Print 2018 Feb 1.

23.

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.

Menicucci AR, Versteeg K, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jankeel A, Geisbert TW, Messaoudi I.

Front Immunol. 2017 Oct 26;8:1372. doi: 10.3389/fimmu.2017.01372. eCollection 2017.

24.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

25.

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW.

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

26.

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2017 Aug 29;7(1):9730. doi: 10.1038/s41598-017-09963-y. Erratum in: Sci Rep. 2019 May 8;9(1):7329.

27.

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.

Mire CE, Geisbert TW.

Trends Mol Med. 2017 Aug;23(8):669-671. doi: 10.1016/j.molmed.2017.06.008. Epub 2017 Jul 8.

28.

Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.

Daaboul GG, Freedman DS, Scherr SM, Carter E, Rosca A, Bernstein D, Mire CE, Agans KN, Hoenen T, Geisbert TW, Ünlü MS, Connor JH.

PLoS One. 2017 Jun 26;12(6):e0179728. doi: 10.1371/journal.pone.0179728. eCollection 2017.

29.

Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models.

Mire CE, Geisbert TW.

Methods Mol Biol. 2017;1628:293-307. doi: 10.1007/978-1-4939-7116-9_24.

PMID:
28573630
30.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

31.

Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses.

Scherr SM, Freedman DS, Agans KN, Rosca A, Carter E, Kuroda M, Fawcett HE, Mire CE, Geisbert TW, Ünlü MS, Connor JH.

Lab Chip. 2017 Feb 28;17(5):917-925. doi: 10.1039/c6lc01528j.

PMID:
28194457
32.

First Ebola virus vaccine to protect human beings?

Geisbert TW.

Lancet. 2017 Feb 4;389(10068):479-480. doi: 10.1016/S0140-6736(16)32618-6. Epub 2016 Dec 23. No abstract available.

33.

Persistence of Ebola virus RNA in seminal fluid.

Geisbert TW.

Lancet Glob Health. 2017 Jan;5(1):e12-e13. doi: 10.1016/S2214-109X(16)30336-9. No abstract available.

34.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
35.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

36.

Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood.

Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW, Mead DA, Chander Y.

J Infect Dis. 2016 Oct 15;214(suppl 3):S234-S242. Epub 2016 Sep 16.

37.

Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D, Hartnett JN, Jones AB, Goba A, Momoh M, Fullah M, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Brown BL, Pham H, Rowland MM, Agans KN, Geisbert JB, Heinrich ML, Kulakosky PC, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Saphire EO, Pitts KR, Khan SH, Grant DS, Geisbert TW, Branco LM, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S210-S217. Epub 2016 Aug 31.

38.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

39.

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH, Robinson JE, Geisbert TW, Garry RF.

Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

40.

Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Boisen ML, Cross RW, Hartnett JN, Goba A, Momoh M, Fullah M, Gbakie M, Safa S, Fonnie M, Baimba F, Koroma VJ, Geisbert JB, McCormick S, Nelson DK, Millett MM, Oottamasathien D, Jones AB, Pham H, Brown BL, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Pitts KR, Geisbert TW, Branco LM, Khan SH, Grant DS, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209. Epub 2016 Aug 11.

41.

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW.

Sci Rep. 2016 Aug 3;6:30916. doi: 10.1038/srep30916.

42.

An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.

Goba A, Khan SH, Fonnie M, Fullah M, Moigboi A, Kovoma A, Sinnah V, Yoko N, Rogers H, Safai S, Momoh M, Koroma V, Kamara FK, Konowu E, Yillah M, French I, Mustapha I, Kanneh F, Foday M, McCarthy H, Kallon T, Kallon M, Naiebu J, Sellu J, Jalloh AA, Gbakie M, Kanneh L, Massaly JL, Kargbo D, Kargbo B, Vandi M, Gbetuwa M, Gevao SM, Sandi JD, Jalloh SC, Grant DS, Blyden SO, Crozier I, Schieffelin JS, McLellan SL, Jacob ST, Boisen ML, Hartnett JN, Cross RW, Branco LM, Andersen KG, Yozwiak NL, Gire SK, Tariyal R, Park DJ, Haislip AM, Bishop CM, Melnik LI, Gallaher WR, Wimley WC, He J, Shaffer JG, Sullivan BM, Grillo S, Oman S, Garry CE, Edwards DR, McCormick SJ, Elliott DH, Rouelle JA, Kannadka CB, Reyna AA, Bradley BT, Yu H, Yenni RE, Hastie KM, Geisbert JB, Kulakosky PC, Wilson RB, Oldstone MB, Pitts KR, Henderson LA, Robinson JE, Geisbert TW, Saphire EO, Happi CT, Asogun DA, Sabeti PC, Garry RF; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2016 Oct 15;214(suppl 3):S110-S121. Epub 2016 Jul 11.

43.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.

44.

Isolation and Characterization of a Novel Gammaherpesvirus from a Microbat Cell Line.

Shabman RS, Shrivastava S, Tsibane T, Attie O, Jayaprakash A, Mire CE, Dilley KE, Puri V, Stockwell TB, Geisbert TW, Sachidanandam R, Basler CF.

mSphere. 2016 Feb 17;1(1). pii: e00070-15. doi: 10.1128/mSphere.00070-15. eCollection 2016 Jan-Feb.

45.

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S263-S267. Epub 2016 Jun 9.

46.

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martínez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF.

Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544.

47.

Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets.

Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, Geisbert TW, Mire CE.

J Virol. 2016 Jun 24;90(14):6326-6343. doi: 10.1128/JVI.00215-16. Print 2016 Jul 15.

48.

Ebola virus vaccines - reality or fiction?

Mire CE, Geisbert TW, Feldmann H, Marzi A.

Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. Epub 2016 May 9. Review.

49.

Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.

Whitt MA, Geisbert TW, Mire CE.

Methods Mol Biol. 2016;1403:295-311. doi: 10.1007/978-1-4939-3387-7_16.

PMID:
27076138
50.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

Supplemental Content

Loading ...
Support Center